Pulse Biosciences Dirección

Dirección controles de criterios 2/4

Pulse Biosciences' El consejero delegado es Kevin Danahy , nombrado en Sep 2022, tiene un mandato de 1.25 años. la remuneración anual total es $2.31M , compuesta por 15.2% salario y 84.8% primas, incluidas acciones y opciones de la empresa. posee directamente 0.065% de las acciones de la empresa, por valor de €306.03K . La antigüedad media del equipo directivo y del consejo de administración es de 1.8 años y 6.1 años respectivamente.

Información clave

Kevin Danahy

Chief Executive Officer (CEO)

US$5.9m

Compensación total

Porcentaje del salario del CEO	7.4%
Permanencia del CEO	1.6yrs
Participación del CEO	0.07%
Permanencia media de la dirección	2.1yrs
Promedio de permanencia en la Junta Directiva	6.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Kevin Danahy en comparación con los beneficios de Pulse Biosciences?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$6m	US$433k	-US$42m
Sep 30 2023	n/a	n/a	-US$39m
Jun 30 2023	n/a	n/a	-US$47m
Mar 31 2023	n/a	n/a	-US$51m
Dec 31 2022	US$2m	US$350k	-US$59m

Compensación vs. Mercado: Kevin($USD2.31M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.06M).

Compensación vs. Ingresos: La compensación de Kevin ha aumentado mientras la empresa no es rentable.

CEO

Kevin Danahy (51 yo)

1.6yrs

Permanencia

US$5,864,450

Compensación

Mr. Kevin P. Danahy is Chief Executive Officer of Pulse Biosciences, Inc. from September 2022 and serves as its President from October 2023 and was its President from September 2022 until 2023. He served a...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Duggan	Executive Chairman	6.4yrs	US$199.20k	67.71% $ 253.4m
Kevin Danahy	President & CEO	1.6yrs	US$5.86m	0.065% $ 243.5k
Darrin Uecker	CTO & Director	1.6yrs	US$5.39m	0.27% $ 1.0m
Mitchell Levinson	Chief Strategy Officer	2.7yrs	US$1.69m	0.18% $ 680.2k
Richard Nuccitelli	Chief Science Officer	9.4yrs	sin datos	sin datos
Kenneth B. Stratton	General Counsel & Corporate Secretary	2.9yrs	sin datos	sin datos
Patty Perla	Vice President of Human Resources	4.3yrs	sin datos	sin datos
David Danitz	Senior Vice President of Engineering	2.6yrs	sin datos	sin datos
Gansevoort Dunnington	Chief Medical Officer	less than a year	sin datos	sin datos
Niv Ad	Chief Science Officer of Cardiac Surgery	less than a year	sin datos	sin datos

2.1yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: 6L8El equipo directivo de la empresa se considera experimentado (2 años de antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Robert Duggan	Executive Chairman	6.4yrs	US$199.20k	67.71% $ 253.4m
Darrin Uecker	CTO & Director	8.6yrs	US$5.39m	0.27% $ 1.0m
Richard van den Broek	Independent Director	3.7yrs	US$151.44k	0% $ 0
Shelley Spray	Independent Director	2.4yrs	US$118.16k	0% $ 0
Mahkam Zanganeh	Independent Director	7.2yrs	US$116.10k	1.37% $ 5.1m
Manmeet Soni	Lead Independent Director	6.4yrs	US$250.34k	0% $ 0

6.4yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de 6L8 se considera experimentada (6.1 años de antigüedad promedio).

Pulse Biosciences Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Executive Chairman recently bought €1.0m worth of stock

Chief Strategy Officer recently bought €97k worth of stock

Pulse Biosciences, Inc. Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery

Pulse Biosciences, Inc. Appoints f Gansevoort 'Gan' Dunnington, M.D. as Its Chief Medical Officer

Pulse Biosciences, Inc. Announces Resignation of Sandra Gardiner as Chief Financial Officer

Chief Strategy Officer & Director recently bought €72k worth of stock

Recent updates

Pulse Biosciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System

Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp

Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter

Executive Chairman recently bought €1.0m worth of stock

Pulse Biosciences, Inc. Announces Filing of Premarket Notification 510(k) to U.S. Food and Drug Administration for its Novel CellFX nsPFA Percutaneous Electrode

Chief Strategy Officer recently bought €97k worth of stock

Pulse Biosciences, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Pulse Biosciences, Inc. Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery

New major risk - Revenue and earnings growth

Pulse Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Pulse Biosciences, Inc. Appoints f Gansevoort 'Gan' Dunnington, M.D. as Its Chief Medical Officer

Pulse Biosciences, Inc. Announces Resignation of Sandra Gardiner as Chief Financial Officer

Pulse Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Chief Strategy Officer & Director recently bought €72k worth of stock

Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions

Pulse Biosciences, Inc. Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia

Pulse Biosciences, Inc. Announces Executive Changes

Pulse Biosciences, Inc. Receives FDA 510(K) Clearance of Expanded Energy Settings for Use with the CellFX System

Pulse Biosciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell 2000 Dynamic Index

Pulse Biosciences, Inc. has completed a Composite Units Offering in the amount of $15 million.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Pulse Biosciences, Inc

Pulse Biosciences, Inc., Annual General Meeting, May 19, 2022

Pulse Biosciences, Inc. to Report Q4, 2021 Results on Mar 31, 2022

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Pulse Biosciences, Inc

Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer

Pulse Biosciences, Inc Provides an Update on Recent FDA 510(k) Submission

Pulse Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter 2021

Forecast to breakeven in 2024

Independent Chairman of the Board recently bought €42m worth of stock

Pulse Biosciences, Inc. Announces First CellFX Procedure Performed in Canada

Pulse Biosciences Announces Health Canada Approval for CellFX® System

Pulse Biosciences® Presents Clinical Study Results of Nano-Pulse Stimulation™ Technology to Clear Benign Lesions at the American Society for Laser Medicine and Surgery (ASLMS) 2021 Virtual Annual Conference

Pulse Biosciences Announces First CellFX Procedures

Pulse Biosciences Announces Start of Controlled Launch of the CellFX System®

Pulse Biosciences, Inc. to Report Q4, 2020 Results on Feb 22, 2021

Pulse Biosciences, Inc. Announces FDA Clearance for the CellFX® System

New 90-day high: €23.60

Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress

New 90-day high: €19.30

New 90-day high: €15.20

Pulse Biosciences, Inc. to Report Q3, 2020 Results on Nov 09, 2020

Pulse Biosciences Announces Presentation of Clinical Results Using Nano-Pulse Stimulation Technology for the Clearance of Skin Lesions at the American Society for Dermatologic Surgery Virtual Annual Meeting

Pulse Biosciences, Inc. Announces FDA IDE Approval and Initiation of Sebaceous Hyperplasia Study

Pulse Biosciences, Inc. Announces the Company Is Not Reasonably Estimate the Future Impact to the Operations and Financial Results

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad